[达托霉素在肾功能不全患者中的安全性]
[Safety of daptomycin in patients with renal impairment].
作者信息
Azanza José Ramón, Quetglas Emilio G
机构信息
Servicio de Farmacología Clínica, Clínica Universidad de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona, España.
出版信息
Med Clin (Barc). 2010 Dec;135 Suppl 3:55-9. doi: 10.1016/S0025-7753(10)70041-5.
Daptomycin is a lipopeptide bactericidal antimicrobial indicated in the treatment of skin and soft tissue infections (SSTI), Staphylococcus aureus-related right-sided infective endocarditis (RIE) and bacteremia secondary to these infections. The recommended dosage in patients with previous renal impairment is 4 mg/kg/48 hours in SSTI. There are no data published for SSTI and RIE followed by bacteremia. Based on pharmacokinetic models, the recommended dosage in patients under hemodialysis is 4 mg/kg after dialysis. The present article aims to review of the latest published data on daptomycin use in patients with renal impairment and to relate these findings to preliminary data from the EUCORE registry in Spain.
达托霉素是一种脂肽类杀菌性抗菌药物，用于治疗皮肤和软组织感染（SSTI）、金黄色葡萄球菌相关的右侧感染性心内膜炎（RIE）以及这些感染继发的菌血症。既往有肾功能损害的患者，SSTI的推荐剂量为4mg/kg/48小时。目前尚无关于SSTI和RIE继发菌血症的相关数据发表。基于药代动力学模型，血液透析患者的推荐剂量为透析后4mg/kg。本文旨在综述有关肾功能损害患者使用达托霉素的最新发表数据，并将这些发现与西班牙EUCORE注册研究的初步数据相关联。
Zotero 插件